CMS Deferred the Third-Party RPM Ban to 2029 — and Cut the Device Payment 21% While It Waited

The rule CMS finalized is narrow and brutal: Medicare pays for RPM and RTM only when the clinical staff doing the work are direct employees of the billing practitioner or practice. Under the proposed rule that began Jan 1, 2027, which would have ended Medicare payment for clinical work performed by contracted monitoring companies. The final rule pushes that to Jan 1, 2029 and lets third-party clinical staffing continue through Dec 31, 2028.

The revaluation is where the money moves. CMS reworked the practice expense behind the setup, device and supply codes by crosswalking them onto lower-valued services, with cuts phased in at no more than 19% in the first year for existing codes. Two new RTM device supply codes, 98978 and 98986, are priced nationally for the first time in 2027 with no first-year phase-in protection.

Put those two decisions side by side and the direction is clear: CMS took money out of the device and transmission half of an episode and left it in the clinical minute. That moves Medicare money from logistics to labor, the exact labor the 2029 rule restricts. A vendor whose model is a shipped device plus an outsourced nurse gets squeezed from both ends, while a platform that already employs its own clinicians and bills for the management minute keeps the value of the work.

The scale of the regulated pool deserves attention before any vendor conclusion. Medicare RPM payments topped $500 million in 2024 and grew 31% from 2023, after enrolment ran from roughly 55,000 beneficiaries in 2019 to 570,000 in 2022. That is real growth inside a small absolute number, and it is the entire fee-schedule pool CMS just revalued and delayed.

Because the requirement reaches clinical staff time and nothing else, it is a labor rule, and labor rules are settled by cash flow. A vendor that must move its nurses onto the payroll of the billing practice, or be acquired by the practice, has to fund that transition while its unit economics are being cut by a fifth. Here is how the listed digital chronic-care cohort stands going into the two-year window.

Two things sit upstream of a Medicare RPM episode: the device that collects the data and the platform that carries it. CMS's final rule protects both. Vendors supplying devices, software, connectivity, data hosting, cybersecurity or technical support remain permitted as long as they do not supply clinical staff time, so the value of an episode migrates toward the device-and-data layer at the same moment its payment shrinks.

Downstream, the buyer sets both price and volume. Medicare Advantage plans decide which conditions they will pay to monitor and what they will pay a vendor per member per month, and the fee schedule CMS just revalued sits inside that negotiation. The deferral changes none of it, which is why the policy story and the revenue story are not the same story.

Between now and the end of 2027 there is no staffing cliff, and that is the only good news in the rule. The pressure shows up in three places instead: the 21.1% cut to device supply, a separately reportable initiating visit on every new episode, and an established-patient limit on RTM, all live on Jan 1, 2027.

The real deadline is 2029, and two calendars decide it: CMS's promised sub-regulatory guidance on whether leased or contracted staff count as employees, and the Jan 2027 RUC review that revalues the practice expense behind all 19 RPM and RTM codes. If leased staff qualify, vendors keep running the clinical work and the deferral becomes a reprieve with teeth. If they do not, only the practice's own employees can be billed, and the vendor becomes a technology supplier to whoever staffs the episode.

Here is the honest version of the call. CMS bought itself two years on a rule it could not defend, and the delay is a genuine reprieve for the small cohort of vendors whose Medicare revenue depends on outsourced clinical work. But it arrives on top of a 21.1% cut to the largest code in an episode, a new visit requirement, a narrowing of RTM eligibility and an untouched 16-day threshold. That combination does not preserve the old model. The rule change rewards the balance sheet, not the technology.